PCYC-1143-CA (SYMPATICO) (R/R)

PCYC-1143-CA (SYMPATICO) (R/R)

Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma  (MCL) (SYMPATICO)


Study Treatments


Inclusion criteria


Exclusion criteria


Participating sites


Link